MedTech Acquisition Corporation (NASDAQ:MTAC) announced this afternoon that it has completed its business combination with drug developer TriSalus Life Sciences.
The deal was initially approved by shareholders at a special meeting held on August 8. A further 890,499 shares were redeemed in the vote, which reduced the SPAC’s trust by $9.4 million, leaving about $2.6 million remaining.
Funds generated in connection to the merger with MedTech, including the proceeds from the recently concluded private placement transaction as well as the funds in the SPAC’s trust, in combination with the available cash on hand, provides a cash runway to support Trisalus’ essential milestones through mid-2024.
TriSalus’ common stock and warrants are now expected to start trading on the Nasdaq under the ticker symbols “TLSI” and “TLSIW,” respectively, on August 11.
MedTech initially announced its $234 million combination with TriSalus Life Sciences in November. Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device
TriSalus plans to have Phase 1 efficacy data for a trial involving multiple doses of its SD-101 candidate in the second half of this year. In April, TriSalus presented clinical data from its Phase I trials using doses of varying size, which indicated positive results in reducing tumor growth in liver cancer patients.
The company’s new board of directors consists of Mats Wahlstrom, Mary Szela, Sean Murphy, Kerry Hicks, Dr. Anil Singhal, Dr. Andrew C. von Eschenbach, Kelly Martin, David J. Matlin and Dr. Arjun (“JJ”) Desai.
Willow Lane (NASDAQ:WLACU) has filed for a $110 million SPAC to be the latest repeat SPAC team returning to the market with the help of underwriter BTIG. BTIG is, in fact, leading recent underwriter activity with four new SPACs filed since the August 1, while no other firm has been left lead for more than...
At the SPAC of Dawn While SPACs settle into a slight pause through Rosh Hashanah, de-SPACs are also entering another period of holiday-based trading patterns. Traders following the usual “Sell in May and Go Away” pattern this year would have missed out on a major late-summer market rally. But, stocks may now feel the effects...
At the SPAC of Dawn As SPACs switch back into gear with a new cycle, traditional IPO road shows are heating up into the fourth quarter as well. A raft of private equity-backed companies have determined now is the time to strike and the period between the Fed’s September rate slash and the November election...
Earth, Wind & Fire may have been on to something with the end of September and “chasin’ the clouds away“. The SPACs from the past are still lingering which are affecting the averages as newly issued SPACs have come to market in the past year. Each has the same goal of bringing a target company...
Ocean Capital Acquisition Corporation (Nasdaq:OCACU) filed this morning for a $60 million offering to be underwritten by Brookline Capital Markets. This is only the second offering for Brookline where they will be in the position of sole bookrunner, with DT Cloud Acquisition Corporation being their first. However, Brookline has been a bookrunner to the right...